-
Mashup Score: 0
The novel MEK inhibitor atebimetinib plus chemo showed early signs of survival benefit in first-line treatment of patients with pancreatic cancer.
Source: www.oncnursingnews.comCategories: General Medicine NewsTweet
The novel MEK inhibitor atebimetinib plus chemo showed early signs of survival benefit in first-line treatment of patients with pancreatic cancer.
An atebimetinib combination demonstrated a potential survival benefit for patients with pancreatic cancer. Read more below. #cancer #oncology #pancreaticcancer #nursing #nurse https://t.co/7H8EvUltSD